Fulcrum Therapeutics granted stock options to new employees at $3.57 per share.

From GlobeNewswire: 2024-10-11 16:30:00

Fulcrum Therapeutics, Inc. granted non-statutory stock options to two new employees, totaling 90,000 options at an exercise price of $3.57 per share. The options have a ten-year term and vest over four years, with 25% of shares vesting on the first anniversary and the rest over twelve quarters. Fulcrum focuses on developing small molecules for rare genetic diseases, with its lead program pociredir targeting sickle cell disease. For more information, visit their website. Contact Chris Calabrese at [email protected] or 917-680-5608 for inquiries.



Read more at GlobeNewswire: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq